74 related articles for article (PubMed ID: 23957481)
21. Reviewing the somatic genetics of melanoma: from current to future analytical approaches.
Dutton-Regester K; Hayward NK
Pigment Cell Melanoma Res; 2012 Mar; 25(2):144-54. PubMed ID: 22248438
[TBL] [Abstract][Full Text] [Related]
22. Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J
J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632
[TBL] [Abstract][Full Text] [Related]
23. The genome and epigenome of malignant melanoma.
Dahl C; Guldberg P
APMIS; 2007 Oct; 115(10):1161-76. PubMed ID: 18042149
[TBL] [Abstract][Full Text] [Related]
24. The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics.
Iwasaki JK; Srivastava D; Moy RL; Lin HJ; Kouba DJ
J Am Acad Dermatol; 2012 May; 66(5):e167-78. PubMed ID: 20800318
[TBL] [Abstract][Full Text] [Related]
25. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
26. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.
Pritchard AL; Hayward NK
Clin Cancer Res; 2013 May; 19(9):2301-9. PubMed ID: 23406774
[TBL] [Abstract][Full Text] [Related]
27. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study.
Gast A; Scherer D; Chen B; Bloethner S; Melchert S; Sucker A; Hemminki K; Schadendorf D; Kumar R
Genes Chromosomes Cancer; 2010 Aug; 49(8):733-45. PubMed ID: 20544847
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
[TBL] [Abstract][Full Text] [Related]
29. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas.
Spencer JM; Kahn SM; Jiang W; DeLeo VA; Weinstein IB
Arch Dermatol; 1995 Jul; 131(7):796-800. PubMed ID: 7611795
[TBL] [Abstract][Full Text] [Related]
30. Genetic alterations and personalized medicine in melanoma: progress and future prospects.
Griewank KG; Scolyer RA; Thompson JF; Flaherty KT; Schadendorf D; Murali R
J Natl Cancer Inst; 2014 Feb; 106(2):djt435. PubMed ID: 24511108
[TBL] [Abstract][Full Text] [Related]
31. TP53 mutations in human skin cancers.
Giglia-Mari G; Sarasin A
Hum Mutat; 2003 Mar; 21(3):217-28. PubMed ID: 12619107
[TBL] [Abstract][Full Text] [Related]
32. [Tumorogenesis and skin tumours in the elderly].
Wild T; Altenburg A; Karagiannidis I; Mauch C; Zouboulis CC
Hautarzt; 2016 Feb; 67(2):132-9. PubMed ID: 26787292
[TBL] [Abstract][Full Text] [Related]
33. Genetics of melanoma.
Wangari-Talbot J; Chen S
Front Genet; 2012; 3():330. PubMed ID: 23372575
[TBL] [Abstract][Full Text] [Related]
34. For the record: the history of precursors to malignant melanoma.
Greene MH; Fraser MC; Clark WH; Elder DE; Guerry D; Kraemer KH
Arch Dermatol; 1984 Jan; 120(1):18-21. PubMed ID: 6691712
[No Abstract] [Full Text] [Related]
35. SMT and TOFT: Why and How They are Opposite and Incompatible Paradigms.
Bizzarri M; Cucina A
Acta Biotheor; 2016 Sep; 64(3):221-39. PubMed ID: 27283400
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic insights into the role of truncating PREX2 mutations in melanoma.
Lissanu Deribe Y
Mol Cell Oncol; 2016 May; 3(3):e1160174. PubMed ID: 27314100
[TBL] [Abstract][Full Text] [Related]
37. Oncogenes in melanoma: an update.
Kunz M
Eur J Cell Biol; 2014; 93(1-2):1-10. PubMed ID: 24468268
[TBL] [Abstract][Full Text] [Related]
38. The genetic basis of new treatment modalities in melanoma.
Kunz M
Curr Drug Targets; 2015; 16(3):233-48. PubMed ID: 25654738
[TBL] [Abstract][Full Text] [Related]
39. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis.
South AP; Purdie KJ; Watt SA; Haldenby S; den Breems N; Dimon M; Arron ST; Kluk MJ; Aster JC; McHugh A; Xue DJ; Dayal JH; Robinson KS; Rizvi SH; Proby CM; Harwood CA; Leigh IM
J Invest Dermatol; 2014 Oct; 134(10):2630-2638. PubMed ID: 24662767
[TBL] [Abstract][Full Text] [Related]
40. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
